Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KZR Kezar Life Sciences	$3.97 -0.3%	$4.35	$3.62 ▼ $9.18	$29.06M	0.65	42,999 shs	42,565 shs
MAAQ Mana Capital Acquisition	$3.63 -9.8%	$4.01	$5.35 ▼ $10.25	$29.49M	N/A	33,075 shs	33,086 shs
MDCX Medicus Pharma	$1.96 -1.0%	$2.74	$1.80 ▼ $8.94	$26.60M	N/A	321,272 shs	186,008 shs
NLSP NLS Pharmaceutics	$2.51 -3.8%	$2.27	$1.30 ▼ $7.44	$9.04M	0.15	154,872 shs	163,014 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KZR Kezar Life Sciences	0.00%	-1.00%	-8.74%	-1.49%	-35.28%
MAAQ Mana Capital Acquisition	0.00%	+5.22%	-21.09%	-5.47%	+758.16%
MDCX Medicus Pharma	0.00%	-0.51%	-36.98%	-74.81%	+195,999,900.00%
NLSP NLS Pharmaceutics	0.00%	+17.29%	+13.06%	+46.78%	+1,305.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KZR Kezar Life Sciences	3.6675 of 5 stars	3.2	0.0	0.0	4.6	2.0	2.5	0.6
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	1.9214 of 5 stars	3.8	0.0	0.0	0.0	1.5	1.7	0.0
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KZR Kezar Life Sciences	2.33	Hold	$9.00	126.70% Upside
MAAQ Mana Capital Acquisition	0.00	N/A	N/A	N/A
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	1,098.98% Upside
NLSP NLS Pharmaceutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NLSP, MDCX, KZR, and MAAQ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/16/2025	KZR Kezar Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
7/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/1/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/23/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KZR Kezar Life Sciences	$7M	4.15	N/A	N/A	$16.02 per share	0.25
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.29 per share	N/A
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	($0.37) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KZR Kezar Life Sciences	-$83.74M	-$9.69	N/A	N/A	N/A	N/A	-63.51%	-52.13%	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	-$11.16M	-$1.34	N/A	N/A	N/A	N/A	-549.30%	-228.06%	N/A
NLSP NLS Pharmaceutics	-$1.98M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest NLSP, MDCX, KZR, and MAAQ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	KZR Kezar Life Sciences	-$2.15	-$1.87	+$0.28	-$1.87	N/A	N/A
8/11/2025	Q2 2025	MDCX Medicus Pharma	-$0.39	-$0.43	-$0.04	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KZR Kezar Life Sciences	0.03	7.29	7.29
MAAQ Mana Capital Acquisition	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	1.29	1.29
NLSP NLS Pharmaceutics	N/A	2.69	2.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KZR Kezar Life Sciences	67.90%
MAAQ Mana Capital Acquisition	68.44%
MDCX Medicus Pharma	N/A
NLSP NLS Pharmaceutics	N/A

Insider Ownership

Company	Insider Ownership
KZR Kezar Life Sciences	9.30%
MAAQ Mana Capital Acquisition	N/A
MDCX Medicus Pharma	11.20%
NLSP NLS Pharmaceutics	16.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KZR Kezar Life Sciences	60	7.32 million	6.64 million	Not Optionable
MAAQ Mana Capital Acquisition	1	8.13 million	N/A	Not Optionable
MDCX Medicus Pharma	N/A	13.57 million	12.05 million	N/A
NLSP NLS Pharmaceutics	6	3.60 million	3.01 million	Not Optionable

NLSP, MDCX, KZR, and MAAQ Headlines

Recent News About These Companies

NLS Pharmaceutics Enters Warrant Exchange Agreement with Alpha Capital

August 14, 2025 | theglobeandmail.com

NLS Pharmaceutics (NASDAQ:NLSP) Upgraded at Wall Street Zen

August 12, 2025 | americanbankingnews.com

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy

July 17, 2025 | prnewswire.com

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

June 30, 2025 | prnewswire.com

NLS Pharmaceutics Ltd.: NLS Pharmaceutics CEO Issues Letter to Shareholders

June 18, 2025 | finanznachrichten.de

NLS Pharmaceutics CEO Issues Letter to Shareholders

June 16, 2025 | prnewswire.com

NLS Pharmaceutics to present Mazindol study at ASCP Meeting

May 22, 2025 | investing.com

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

May 21, 2025 | prnewswire.com

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

April 15, 2025 | prnewswire.com

NLS Pharmaceutics, Kadimastem announce up to $3M equity financing

April 1, 2025 | markets.businessinsider.com

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

March 31, 2025 | accessnewswire.comA

NLS Pharmaceutics CEO Issues Letter to Shareholders

March 10, 2025 | prnewswire.com

NLS Pharmaceutics announces new preclinical data for AEX-2

February 27, 2025 | markets.businessinsider.com

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

February 27, 2025 | prnewswire.com

NLS Pharmaceutics and Kadimastem complete pre-IND diabetes meeting with FDA

February 25, 2025 | markets.businessinsider.com

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

February 25, 2025 | prnewswire.com

NLS Pharmaceutics files $75M mixed securities shelf

February 11, 2025 | markets.businessinsider.com

NLS and Kadimastem to merge, aim for diabetes care innovation

February 10, 2025 | msn.com

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

February 10, 2025 | prnewswire.com

NLS Pharmaceutics files to sell 645,161 common shares for holders

February 5, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLSP, MDCX, KZR, and MAAQ Company Descriptions

Kezar Life Sciences NASDAQ:KZR

$3.97 -0.01 (-0.25%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.94 -0.03 (-0.76%)

As of 05:06 AM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Mana Capital Acquisition NASDAQ:MAAQ

$3.63 -0.39 (-9.77%)

As of 08/15/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

Medicus Pharma NASDAQ:MDCX

$1.96 -0.02 (-1.01%)

As of 08/15/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

NLS Pharmaceutics NASDAQ:NLSP

$2.51 -0.10 (-3.83%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.62 +0.11 (+4.38%)

As of 06:42 AM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time